Mangalam Drugs & Organics Limited

NSE MANGALAM.NS

Mangalam Drugs & Organics Limited Operating Income Margin for the year ending March 31, 2024: 0.75%

Mangalam Drugs & Organics Limited Operating Income Margin is 0.75% for the year ending March 31, 2024, a -81.51% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Mangalam Drugs & Organics Limited Operating Income Margin for the year ending March 31, 2023 was 4.04%, a -53.40% change year over year.
Mangalam Drugs & Organics Limited Operating Income Margin for the year ending March 31, 2022 was 8.67%, a -25.44% change year over year.
Mangalam Drugs & Organics Limited Operating Income Margin for the year ending March 31, 2021 was 11.63%, a 111.41% change year over year.
Mangalam Drugs & Organics Limited Operating Income Margin for the year ending March 31, 2020 was 5.50%, a 365.90% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NSE: MANGALAM.NS

Mangalam Drugs & Organics Limited

CEO	Mr. Govardhan Murlidhar Dhoot
IPO Date	May 23, 2005
Location	India
Headquarters	Rupam Building
Employees	432
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials

Description

Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.

Key trends

Past 5 years